GLP1R and type 2 diabetes mellitus: In addition to myriad studies in adults, the GLP-1 agonist, Liraglutide, has been shown to be effective in reducing hemoglobin A1c in youth with type 2 diabetes (146) and promoting weight loss in obese adolescents with no evidence of dysglycemia (147).